Cite

HARVARD Citation

    Rakocevic, G. et al. (2018). Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurology. 5 (4), p. . [Online]. 
  
Back to record